Pfizer Inc PFE

$28.89 +0.06 (0.21%)

Valuation

Market cap
164,668,784,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.45
P/E (forward)
9.47
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
21,598,700
Avg volume
33,090,832
Day's range
$28.62 – $28.99
Shares out
5,699,854,000
Stochastic %K
12%
Beta
0.31
Analysts
Hold
Price target
$30.53

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

TalkMarkets Nov 16, 3:23 PM
BridgeBio Pharma: Surviving Was Just the Beginning $BBIO $PFE $XBI https://talkmarkets.com/article/bridgebio-pharma-surviving-was-just-the-beginning
0 replies
Micheal_Pothead Nov 16, 3:04 PM
$PFE I can’t believe I should have stayed here 🫩
1 replies
PFElinepfrenzy1990 Nov 16, 2:54 PM
$PFE - I bully my shitco every day
0 replies
phoenixblaze Nov 16, 2:19 PM 1 replies
H143capital Nov 16, 1:55 PM
$BBIO Surviving was just the beginning. Can BridgeBio turn Attruby into the foundation for its next chapter? $NRIX $ALNY $PFE $BHVN My latest deep dive covers the pipeline, debt, upcoming catalysts and bull/bear valuation cases. Long BBIO. Here’s what I’m watching next 👇 https://h143capital.substack.com/p/bridgebio-pharma-surviving-was-just?r=8sxi6s&utm_medium=ios
0 replies
Quantumup Nov 16, 12:45 PM
BTIG reiterated $JBIO Buy-$77 and said--JBIO continues to execute as multiple key catalysts approach, with the Phase 3 (EVERGREEN) trial of JADE101 in IgAN expected to initiate later in 4Q26 and the ongoing Phase 2 (JUNIPER) trial expected to deliver interim data in 2Q27. [ $OTSKY TVTX VERA VRTX [ $PFE ROIV AZN ARGX [NVS BIIB - RHHBY AMGN]]] BTIG went on to say: https://x.com/Quantumup1/status/2122309852609298530?a=Df3hFeFqR1faVJEGvTM&s=20
0 replies
DefiDynasty Nov 16, 12:24 PM
$PFE volume picking up today, more activity than usual. Watching to see if it holds through the close. Not reading too much into it yet. Just tracking the flow.
0 replies
truthseeeker Nov 16, 11:55 AM
$PFE 's move down from $30 plus is perfectly appropriate given the reality that it is clear that the FED will be hiking multiple times as PFE , given it obvious lack of growth potential makes its investment thesis be almost solely on it dividend which is not rising and therefore suffers as risk free rate of treasury bills rises. As such I would look upon any PFE rally as a selling opportunity , especially anything approaching $30 or above.. The patent cliff is real and will become more obvious as time moves closer to that cliff.............
0 replies